AMPEL’s Genomic Platform (AGP®)
AMPEL’s Genomic Platform (AGP®) consists of bioinformatic tools, RNA analytics, and machine learning algorithms (AI/ML), which analyze gene expression
Technology & Advantages
The AGP® evaluates disease status, identifies molecular pathways, and predicts drug options
Suite of Tools
AMPEL’s genomic platform (AGP®) powers precision medicine by hosting a suite of proprietary tools to identify, analyze, predict and prioritize targets for drug development from microarray or RNAseq experiments regardless of disease.
AGP® is powered by a database containing genomic information from 15,000+ autoimmune patients including clinical information (more autoimmune and inflammatory diseases coming soon) and 5,000+ healthy individuals.
Unique AI and ML tools all organized into specific pipelines allowing rapid, efficient and accurate analysis.
From RNA To Comprehensive Insight
Combining Analytics and Machine Learning to Understand Individual Disease Mechanisms and Endotypes.
AMPEL LUPUS Solution
The AMPEL Genomic Platform (AGP®) Enables Personalized Precision Care.
Tests of autoantibodies and complement.
Identify disease status & drug options precisely.